15% OFF $150+· CodeFALL15
Ends October 15Shop now
Lot certificates published
Plain, secure packaging

same family

Tirzepatide vs Retatrutide

Tirzepatide and retatrutide are distinct members of the Library’s multi-receptor incretin analog class, with separate development codes and molecular identities.

Published: 2026-10-03Library record comparison: 2026-10-03

01

Identity side by side

Recorded molecular identities of Tirzepatide and Retatrutide
Recorded fieldTirzepatideRetatrutide
Canonical nameTirzepatideRetatrutide
Aliasesnot recordednot recorded
Development codesLY3298176LY3437943
CAS2023788-19-22381089-83-2
UNIInot recordedNOP2Y096GV
PubChem CID166567236not recorded
Molecular formulaC225H348N48O68not recorded
Molecular weight (Da)4813not recorded
Sequence length (residues)39not recorded
Terminal modificationsFree N-terminus; C-terminal amide at Ser39not recorded
Structural modificationsFatty-acid moiety linked to the peptide backbonenot recorded

Tirzepatide: nomenclature notes

The discovery record identifies the molecule under the development code LY3298176. PubChem lists no UNII for this record, so no UNII is published here.

Retatrutide: nomenclature notes

Retatrutide is the adopted name used for the development compound LY3437943 in the verified bibliography.

02

Recorded modification details

An aligned one-letter sequence is not recorded for this pair. The stored modification and sequence notes are shown below.

Tirzepatide

Terminal modifications
Free N-terminus; C-terminal amide at Ser39
Structural modifications
Fatty-acid moiety linked to the peptide backbone
Stored three-letter notation
Tyr · Aib · Glu · Gly · Thr · Phe · Thr · Ser · Asp · Tyr · Ser · Ile · Aib · Leu · Asp · Lys · Ile · Ala · Gln · Lys · Ala · Phe · Val · Gln · Trp · Leu · Ile · Ala · Gly · Gly · Pro · Ser · Ser · Gly · Ala · Pro · Pro · Pro · Ser · NH2
Sequence notes
Thirty-nine residues numbered from the N-terminus, with the C-terminal amide carried as the trailing NH2 token. NO one-letter string is published here: positions 2 and 13 are both Aib, 2-aminoisobutyric acid, and no standard letter names that residue. Residue 1 is Tyr, the GIP N-terminus rather than GLP-1's His. There are two lysines, at 16 and 20, and the acylation site is Lys20. The backbone is not the whole molecule: that Lys20 side chain is acylated through two AEEA spacers and a gamma-L-glutamyl unit to a C20 dicarboxylic fatty acid. Summing the thirty-nine residues with Aib at 2 and 13, removing thirty-eight waters, applying the Ser39 amide, then adding two AEEA units, one glutamyl unit and eicosanedioic acid less the four waters of the four amide bonds, gives C225H348N48O68, reproducing the recorded formula exactly; the derived average mass is 4813.53 Da against a recorded 4813, which is a truncation of that value rather than a rounding of it. Residues 29 to 39 are Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser; that tail is shared with other 39-residue incretin peptides and is not by itself evidence of ancestry, which the structural notes take up. That arithmetic is the identity check this record rests on; the automated sequence verifier cannot reach it, because Aib and the acyl side chain are outside its derivation model.

Retatrutide

Terminal modifications
not recorded
Structural modifications
not recorded

03

Recorded mechanisms

These lists show the links recorded in each monograph. An unlisted link does not establish its absence from the molecule’s biology.

Recorded only for Tirzepatide

not recorded

Recorded only for Retatrutide

04

Recorded compound classes

Shared recorded links

Recorded only for Tirzepatide

not recorded

Recorded only for Retatrutide

not recorded

05

References for the relationship

  1. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.

    Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, Cabrera O, Roell WC, Kuchibhotla U, Moyers JS, Benson CT, Gimeno RE, D'Alessio DA, Haupt A

    Molecular metabolism · 2018-10-03 · Journal Article

    current
  2. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.

    Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, O'Farrell LS, Briere DA, Sloop KW, Thomas MK, Pirro V, Wainscott DB, Willard FS, Abernathy M, Morford L, Du Y, Benson C, Gimeno RE, Haupt A, Milicevic Z

    Cell metabolism · 2022-08-18 · Journal Article

    current

06

Read the full monographs